COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the
safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in
combination with COM701 in subjects with advanced malignancies.